GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » EV-to-FCF

Kaken Pharmaceutical Co (TSE:4521) EV-to-FCF : (As of May. 01, 2024)


View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Kaken Pharmaceutical Co's Enterprise Value is 円69,372 Mil. Kaken Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was 円0 Mil. Therefore, Kaken Pharmaceutical Co's EV-to-FCF for today is .

The historical rank and industry rank for Kaken Pharmaceutical Co's EV-to-FCF or its related term are showing as below:

TSE:4521' s EV-to-FCF Range Over the Past 10 Years
Min: 6.77   Med: 19.36   Max: 19.79
Current: 9.47

During the past 13 years, the highest EV-to-FCF of Kaken Pharmaceutical Co was 19.79. The lowest was 6.77. And the median was 19.36.

TSE:4521's EV-to-FCF is ranked better than
79.84% of 511 companies
in the Drug Manufacturers industry
Industry Median: 22.28 vs TSE:4521: 9.47

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-01), Kaken Pharmaceutical Co's stock price is 円3477.00. Kaken Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was 円78.043. Therefore, Kaken Pharmaceutical Co's PE Ratio for today is 44.55.


Kaken Pharmaceutical Co EV-to-FCF Historical Data

The historical data trend for Kaken Pharmaceutical Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co EV-to-FCF Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.64 5.00 7.66 7.63 9.74

Kaken Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 9.74 - - -

Competitive Comparison of Kaken Pharmaceutical Co's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaken Pharmaceutical Co's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's EV-to-FCF falls into.



Kaken Pharmaceutical Co EV-to-FCF Calculation

Kaken Pharmaceutical Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=69371.601/0
=

Kaken Pharmaceutical Co's current Enterprise Value is 円69,372 Mil.
Kaken Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kaken Pharmaceutical Co  (TSE:4521) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Kaken Pharmaceutical Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3477.00/78.043
=44.55

Kaken Pharmaceutical Co's share price for today is 円3477.00.
Kaken Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円78.043.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Kaken Pharmaceutical Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaken Pharmaceutical Co (TSE:4521) Business Description

Traded in Other Exchanges
Address
28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (TSE:4521) Headlines

No Headlines